Raf Kinase Inhibitor Protein Regulation of Raf and MAPK Signaling

Methods in Enzymology

Volumn 407, Issue , 2006, Pages 248-259

  Hagan, Suzanne ^a   Garcia, Rey ^a   Dhillon, Amardeep ^a   Kolch, Walter ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR KINASE 2; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; RAF PROTEIN; RAS PROTEIN;

DISSOCIATION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; METASTASIS; MULTIGENE FAMILY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 33744542795     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(05)07021-7     Document Type: Review

References (21)

1. Alessi D.R., Cohen P., Ashworth A., Cowley S., Leevers .J., and Marshall C.J. Assay and expression of mitogen-activated protein kinase, MAP kinase kinase, and Raf. Methods Enzymol. 255 (1995) 279-289
2. Banfield M.J., Barker J.J., Percy A.C., and Brady R.L. Function from structure? The crystal structure of human phosphatidylethanolamine-binding protein suggests a role in membrane signal transduction. Structure 6 (1998) 1245-1254
3. Boldt S., and Kolch W. Targeting MAPK signalling: Prometheus' fire or Pandora's box?. Curr. Pharm. Des. 10 (2004) 1885-1905
4. Chatterjee D., Bai Y., Wang Z., Beach S.M., Mott S., Roy R., Braastad C., Sun Y., Mukhopadlyay A., Aggarwal BB., Darnowski J., Pantazis P., Wyche J., Fu Z., Kitagwa Y., Keller E.T., Sedivy J.M., and Yeung K.C. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J. Biol. Chem. 279 (2004) 17515-17523
5. Fu Z., Smith P.C., Zhang L., Rubin M.A., Dunn R.L., Yao Z., and Keller E.T. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J. Natl. Cancer Inst. 95 (2003) 878-889
6. Gardner A.M., Vaillancourt R.R., and Johnson G.L. Activation of mitogen-activated protein kinase/extracellular signal regulated kinase kinase by G protein and tyrosine kinase oncoproteins. J. Biol. Chem. 268 (1993) 17896-17901
7. Greten F.R., and Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 206 (2004) 193-199
8. Häfner S., Adler H.S., Mischak H., Janosch P., Heidecker G., Wolfman A., Pippig S., Lohse M., Ueffing M., and Kolch W. Mechanism of inhibition of Raf-1 by protein kinase A. Mol. Cell. Biol. 14 (1994) 6696-6703
9. Hengst U., Albrecht J., Hess D., and Monard D. The phosphatidylethanolamine-binding protein is the prototype of a novel family of serine protease inhibitors. J. Biol. Chem. 276 (2001) 535-540
10. Lorenz K., Lohse M.J., and Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature 426 (2003) 574-579
11. O'Neill E., and Kolch W. Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br. J. Cancer 90 (2004) 283-288
12. Park S., Yeung M.L., Beach S., Shields J.M., and Yeung K.C. RKIP down-regulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24 (2005) 3535-3540
13. Schuierer M.M., Bataille F., Hagan S., Kolch W., and Bosserhoff A.K. Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. Cancer Res. 64 (2004) 5186-5192
14. Serre L., Vallee B., Bureaud N., Schoentgen F., and Zelwar C. Crystal structure of the phosphatidylethanolamine-binding protein from bovine brain: A novel structural class of phospholipid-binding proteins. Structure 6 (1998) 1255-1265
15. Shi S.R., Key M.E., and Kalra K.L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 39 (1991) 741-748
16. Simister P.C., Banfield M.J., and Brady R.L. The crystal structure of PEBP-2, a homologue of the PEBP/RKIP family. Acta Crystallogr. D. Biol. Crystallogr. 58 (2002) 1077-1080
17. Wang X., Li N., Liu B., Sun H., Chen T., Li H., Qui J., Zhang L., Wan T., and Cao X. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J. Biol. Chem. 279 (2004) 45855-45864
18. Wellbrock C., Karasarides M., and Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell. Biol. 5 (2004) 875-885
19. Yeung K., Janosch P., McFerran B., Rose D.W., Mischak H., Sedivy J.M., and Kolch W. Mechanism of suppression of the Raf/MEK/Extracellular signal-regulated kinase pathway by the raf kinase inhibitor protein. Mol. Cell. Biol. 20 (2000) 3079-3085
20. Yeung K., Seitz T., Li S., Janosch P., McFerran B., Kaiser C., Fee F., Katsanakis K.D., Rose D.W., Mischak K.H., Sedivy J.M., and Kolch W. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401 (1999) 173-177
21. Yeung K.C., Rose D.W., Dhillon A.S., Yaros D., Gustafsson M., Chatterjee D., McFerran B., Wyche J., Kolch W., and Sedivy J.M. Raf kinase inhibitor protein interacts with nf-kappab-inducing kinase and tak1 and inhibits nf-kappab activation. Mol. Cell. Biol. 21 (2001) 7207-7217